Atopic dermatitis, also known as eczema, is a skin condition that causes red, itchy, and scaly patches on the skin. It affects people of all ages, but it's more common in children. We don't know exactly what causes it, but it's believed to be caused by a mix of things like genes, environmental factors, allergens, and irritants. Atopic dermatitis can make people feel uncomfortable and unhappy, but there are some treatments available to help manage the symptoms.
However, many people with moderate-to-severe atopic dermatitis still have trouble managing their symptoms. A clinical trial tested a new treatment that combines two medicines called lebrikizumab and topical corticosteroids. The trial showed that this treatment improved outcomes in people with moderate-to-severe atopic dermatitis more than using topical corticosteroids alone.
Lebrikizumab is a type of medicine that stops a protein called interleukin-13 from developing. This protein is believed to play a role in the development of atopic dermatitis. The trial was done with 211 patients who had moderate-to-severe atopic dermatitis. The patients were from Germany, Poland, Canada, and the United States. The trial was done over a year and a half, from February 3, 2020, to September 16, 2021.
Clinical Trial Results
The results of the trial showed that the combination of lebrikizumab and topical corticosteroids was better than using only topical corticosteroids. Specifically, at week 16, 41.2% of patients in the lebrikizumab group had much better scores than at the start of the trial, compared to only 22.1% in the group that didn't get lebrikizumab. The lebrikizumab group also had less itch and better quality of life.
The new treatment was also safe, with most people not having any serious side effects. Some people had mild or moderate side effects like conjunctivitis (pink eye), headaches, high blood pressure, reactions at the injection site, and herpes infection.
This new treatment combining lebrikizumab and topical corticosteroids has shown promising results in improving outcomes in people with moderate-to-severe atopic dermatitis. This could be an important option for people who have trouble managing their symptoms with current treatments. But we need more studies to be sure that the treatment is safe and effective in the long term.__________